HALOZYME THERAPEUTICS, INC. Quarterly Income Tax Expense (Benefit) in USD from Q2 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Halozyme Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2015 to Q3 2024.
  • Halozyme Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $28.1M, a 41.2% increase year-over-year.
  • Halozyme Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $87.6M, a 36.8% increase year-over-year.
  • Halozyme Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $66.7M, a 42.6% increase from 2022.
  • Halozyme Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $46.8M.
  • Halozyme Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was -$154M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $87.6M $28.1M +$8.21M +41.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $79.4M $24.5M +$6.1M +33.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $73.3M $19.2M +$6.58M +52.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $66.7M $15.8M +$2.7M +20.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $64M $19.9M +$7.85M +65% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $56.2M $18.4M +$11.1M +151% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $45.1M $12.6M -$1.68M -11.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $46.8M $13.1M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 $12.1M +$155M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $7.33M +$7.27M +12531% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $14.3M +$14.1M +7387% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q3 2021 -$142M -$142M* -$143M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $397K $58K $0 0% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $397K $191K +$180K +1636% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $217K $85K +$148K Oct 1, 2020 Dec 31, 2020 10-K 2023-02-21
Q3 2020 $69K $63K +$50K +385% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 $19K $58K +$41K +241% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$22K $11K -$11K -50% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$11K -$63K -$380K -120% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-22
Q3 2019 $369K $13K +$13K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-02
Q2 2019 $356K $17K -$16K -48.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $372K $22K -$165K -88.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $537K $317K +$2.65M Oct 1, 2018 Dec 31, 2018 10-K 2021-02-23
Q3 2018 -$2.11M $0 -$580K -100% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$1.53M $33K -$147K -81.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 -$1.38M $187K -$23K -11% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 -$1.36M -$2.33M -$1.91M -452% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-24
Q3 2017 $548K $580K -$704K -54.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $1.25M $180K -$120K -40% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $1.37M $210K +$210K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 $1.16M -$422K Oct 1, 2016 Dec 31, 2016 10-K 2019-02-21
Q3 2016 $1.28M +$1.28M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $300K +$300K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 $0 Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q3 2015 $0 Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-07
Q2 2015 $0 Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.